1. Home
  2. SPT vs ANNX Comparison

SPT vs ANNX Comparison

Compare SPT & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprout Social Inc

SPT

Sprout Social Inc

N/A

Current Price

$11.17

Market Cap

730.1M

Sector

Technology

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

N/A

Current Price

$4.28

Market Cap

726.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPT
ANNX
Founded
2010
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
730.1M
726.1M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
SPT
ANNX
Price
$11.17
$4.28
Analyst Decision
Hold
Buy
Analyst Count
10
10
Target Price
$13.17
★ $17.00
AVG Volume (30 Days)
829.3K
★ 3.6M
Earning Date
11-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 32.11
N/A
EPS
★ N/A
N/A
Revenue
★ $457,547,000.00
N/A
Revenue This Year
$8.24
N/A
Revenue Next Year
$3.68
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 12.72
N/A
52 Week Low
$4.92
$2.54
52 Week High
$13.35
$7.18

Technical Indicators

Market Signals
Indicator
SPT
ANNX
Relative Strength Index (RSI) 45.50 56.67
Support Level $6.22 $3.71
Resistance Level $11.75 $4.37
Average True Range (ATR) 0.65 0.26
MACD -0.21 0.06
Stochastic Oscillator 25.25 73.86

Price Performance

Historical Comparison
SPT
ANNX

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: